Boehringer, Lilly creep up on Sanofi with Lantus biosimilar

Eli Lilly ($LLY) and Boehringer Ingelheim say their in-development Lantus biosimilar proved safe and effective as its reference treatment across 6 clinical trials. The two intend to launch the drug overseas when Sanofi's insulin comes off patent next year, but pending litigation could prolong a U.S. debut until 2016. More